Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.

Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.

Obesity

Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification

Liraglutide

placebo

Xiangya Hospital of Central South University

Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities

Efficacy and Safety of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 28-week Trial

mean change from baseline in fasting body weight (%) after 28-weeks of treatment.

Percentage of subjects losing at least 5% of baseline fasting body weight after 28-weeks of treatment.

Percentage of subjects losing >10% of baseline fasting body weight after 28-weeks of treatment

mean change from baseline in waist circumference (cm) after 28-weeks of treatment

LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

Bipolar Disorder

3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

LIRAGLUTIDE

Placebo

Lindner Center of HOPE

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder

The primary objective of this study is to evaluate the efficacy of liraglutide 3.0 mg sc injection(in combination with a reduced calorie diet and increased physical activity) compared with placebo for reducing body weight in obese or overweight adults with stable BP, as measured by percent change in body weight.

Susan McElroy

Chief Research Officer

We will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP.

multiple endocrine neoplasia/затлъстяване

Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Най-пълната база данни за лечебни билки, подкрепена от науката